Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Net Margin (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Net Margin data on record, last reported at 184.87% in Q4 2025.

  • For Q4 2025, Net Margin rose 48295.0% year-over-year to 184.87%; the TTM value through Dec 2025 reached 291.74%, up 422.0%, while the annual FY2025 figure was 292.02%, 394.0% up from the prior year.
  • Net Margin reached 184.87% in Q4 2025 per CCCC's latest filing, up from 286.43% in the prior quarter.
  • Across five years, Net Margin topped out at 77.99% in Q4 2021 and bottomed at 1348.42% in Q2 2023.
  • Average Net Margin over 5 years is 498.72%, with a median of 327.03% recorded in 2021.
  • Peak YoY movement for Net Margin: plummeted -120386bps in 2022, then surged 120086bps in 2024.
  • A 5-year view of Net Margin shows it stood at 77.99% in 2021, then tumbled by -1544bps to 1281.85% in 2022, then increased by 17bps to 1065.84% in 2023, then skyrocketed by 37bps to 667.82% in 2024, then soared by 72bps to 184.87% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 184.87% in Q4 2025, 286.43% in Q3 2025, and 402.6% in Q2 2025.